Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2[kd/kd] Mice
-
- Hatano Ryo
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
-
- Kawaguchi Kotoku
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
-
- Togashi Fumitaka
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
-
- Sugata Masato
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
-
- Masuda Shizuka
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
-
- Asano Shinji
- Department of Molecular Physiology, College of Pharmaceutical Sciences, Ritsumeikan University
書誌事項
- タイトル別名
-
- Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in <i>Vil2<sup>kd</sup></i><sup>/</sup><i><sup>kd</sup></i> Mice
この論文をさがす
説明
<p>Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid that possesses many pharmacological effects, including increasing bile flow, changing the hydrophobicity of the bile acid pool, and modulation of the immune response. UDCA has been approved for treating cholestatic liver disease, such as primary biliary cholangitis. However, several unanticipated severe side effects of UDCA are observed in cholestatic patients, and its pharmacological benefits remain controversial. We reported that ezrin-knockdown (Vil2kd/kd) mice exhibited severe hepatic injury because of a functional disorder in bile duct fluidity and alkalinity regulation, resembling human intrahepatic cholestatic disease. Here we used Vil2kd/kd mice as a cholestatic model to investigate the pharmacological effects of UDCA. We investigated the effects of oral and parenteral administration of UDCA on Vil2kd/kd mice. In Vil2kd/kd mice, fed a 0.5% (w/w) UDCA diet for 3 weeks, hepatic injury was exacerbated, although oral administration of a lower dose of UDCA slightly improved hepatic function in Vil2kd/kd mice. On the other hand, intraperitoneal administration of UDCA (50 mg/kg/d) ameliorated hepatic function and markedly reduced periductal fibrosis and cholangiocyte proliferation in Vil2kd/kd mice although biliary pH and HCO3− concentration were not improved. The expression levels of inflammatory and profibrotic genes were also significantly decreased in these mice. Furthermore, UDCA prevented cholangiocytes from hydrophobic bile acid-induced cytotoxicity independent of extracellular pH in in vitro experiments. These results suggest that an appropriate dosage of UDCA can ameliorate the intrahepatic cholestasis in Vil2kd/kd mice without changing the biliary bicarbonate secretion.</p>
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 40 (1), 34-42, 2017
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679609533696
-
- NII論文ID
- 130005188793
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 027818768
-
- PubMed
- 28049946
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可